The CL detected with a picou'rz Model 6100 luminometer, from Packard Instrument Co., Downers Grove, IL 60515, was 35 x 106 counta/20 5, 33 X iO countal20 s, and 21 x 106 counts/20 s, and the signal/noise ratio was 20:1, 60:1, and 5000:1 for the horseradish peroxidase system, the microperoxidase system, and the glucose oxidase system, respectively.
The glucose oxidase system can also be used to quantify CL response in a solid-phase system. In this test, polyacrylamide beads (Immunobead Reagent; Bio-Rad Laboratories, Richmond, CA 94804) are coupled with human IgG by use of the aqueous carbodiimide reaction (5, 6). Luminol, converted to the diazomum salt with nitric acid, is reacted at alkaline pH with the protein with which the beads were coated (4). The luminol-conjugated beads are then washed with PBS to remove unattached luminol.
To estimate the amount of luminol beads and correlate it with the CL label they carried, we mixed the bead suspension with an equal volume of 100 mg/L toluidine blue 0 (from Sigma) for easier counting in a hemacytometer.
The 120-pL assay mixture consists of 60 pL of PBS, 10 p1 of 100 gfL glucose solution, 0.1 pg of microperoxidase in 10 p1 of PBS, and various numbers of luminol beads. Ten microlitars (0.64 U) of glucose oxidase is injected to initiate the coupled luminescence reaction, which is carried out at 37#{176}C. Light response, integrated for 20 a, correlates linearly with the number of luminol beads (5 x 104to5 x iO luminol beads). With x = log value of number of beads andy = CL response (log value of counts per 20 s), linear regression analysis of the data gave the regression equation y = 0.918x -0.506, with r = 0.996. The lowest detectable signal is at least sixfold over background level. The glucose-oxidasecoupled enzyme system described above provides an example of a simple and reliable method of quantifying CL labels in a neutral pH environment. tubes, of serum samples derived from blood collected in evacuated silicon-coated tubes. As they and others (9) noted, other RIA methods are not affected by this circumstance.
Nevertheless, their studies involved few euthyroidal individuals, and the possible relationship between abnormal increases in FF4 results and the true FF4 concentration was not studied. Here we report a study in which we checked the effect on FF4 of sample collection into siliconized tubes in a large set of samples involving a wide range of FF4 concentrations.
We collected blood from 125 patients selected without conscious bias from outpatients referred to our department for measurement of thyroid hormones in serum. Samples from each subject were collected in both siliconized (5SF Vacutainer Systems; Becton-Dickinson & Co.,Rutherford, NJ) and nonsiliconized evacuated glass tubes. The serum obtained was stored at -40 #{176}C until assayed. We measured FF4 concentrations by RIA with antibody-coated tubes ('Fwo-Step" GammaCoat;
Clinical Assays, Cambridge, MA) according to the manufacturers instructions, except for longer incubation time than recommended (60 mm vs 20 mm) for the reaction between sample and antibody, and also use of 37 #{176}C instead of room temperature in incubation involving the 'I-labelod thyroxin and antibody.
Paired samples from the same subjects were measured in the same batch to avoid between-run variation. Within-run CV, as evaluated from 10 control serum replicates, run at three different concentrations, was 8.8,7.5, and 11.5% for low, normal, and high concentrations of FF4. Statistical differences between FF4 from siliconized and nonsiiconized collection tubes were tested by Wilcoxon's paired-test. Slope and y-intercept values for the regression line between paired FF4 values were estimated by least-square regression. Linearity of the regression line was tested by analysis of variance, and confidence intervals for regression parameters were calculated at the 0.05 level of statistical significance. This increase in FF4 appears to be related to FF4 concentration, because it was noticeable only for samples with normal or low concentrations of FF4. Thus, when assessing FF4 concentrations with the (3ammnCoat "Two-Step" kit, one should take into account, among other things, the type of serum sample used for the assay, particularly if the reference intervals are based on different sample-collection conditions. Wereportforthefirsttimethefalsepositive appearance of amphetamines by both the Syva EMIT-d.a.u. assay as well as on the Marion Laboratory ToxiLab A urine screen in a 69-year-old woman being treated for hypertension with the drug labetalol ('Normodyne," Schering Corp.). In addition, the ToxiLab A screen gave the false impression of the presence of trimethoprim and its metabolites.
On the seventh day after admission for treatment of malignant hypertension, a routine basic drug urine screen was requested. The toxicology laboratory reported a positive result for amphetamine by the EMIT-d.a.u. assay (1). The Toxi-Lab A screen, involving thinlayer chromatography (2), showed migration patterns (Rf values) and color characteristics extraordinarily similar to amphetamine and methamphetamine. In stage I, however, the color characteristic of the unknown drug was slightly more orange than amphetamine. In stage ifi, the migration patterns and color characteristics of two other unknown spots were indicative of trimethoprim and its metabolite.
Upon reporting our findings, we were immediately contacted by the clinician attending the patient. He informed us that the patient was neither receiving nor had access to either drug, amphetamine and trimethoprim, reported by the laboratory. Repeating the urine screen on the same urine above as well as a newly collected specimen (27 h later) showed results similar to those described above. We also observed a positive result for amphetamines with the EMrr-d.a.u. confirmatory procedure (1).
After reviewing the patient's chart, we noted that the only medications the patient was receiving were cimetidine, ranitidine, nitroprusside, and labetalol (Normodyne, 300 mg, orally, twice a day The metabolism of labetalol, an adrenergic receptor blocking agent used in the treatment of hypertension, is mainly through conjugation to glucuronide metabolites (3), present in plasma and excreted in the urine. About 55 to 75% of a dose appears in the urine as conjugates or unchanged labetalol within 24 h of dosing. Apparently, when labetalol is given therapeutically for the treatment of hypertension, the parent drug (secondary amine) and its metabolites both cross react with antibodies in Syva's urine screen for drug abuse. This cross reactivity may be ascribable to the 1-methyl-3-phenyl-propylamino side chain on labetalol, making it structurally sixthlar to amphetamine-like drugs. At present, we also cannot account for the similarity of a false-positive pattern for' the pyrimidine-derivative trimethoprim, by the Toxi-Lab A system. Thus, clinical toxicology laboratories should be cognizant of these potential sources of error (false-positive results) when these methods are used to screen for drugs of abuse.
